{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,22]],"date-time":"2025-10-22T17:59:18Z","timestamp":1761155958560},"reference-count":23,"publisher":"Japanese Society of Internal Medicine","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.4274","type":"journal-article","created":{"date-parts":[[2015,6,14]],"date-time":"2015-06-14T22:04:20Z","timestamp":1434319460000},"page":"1553-1557","source":"Crossref","is-referenced-by-count":6,"title":["Successful Treatment with Infliximab for Refractory Uveitis in a Hemodialysis Patient with Beh&amp;ccedil;et's Disease and a Review of the Literature for Infliximab Use in Patients on Hemodialysis"],"prefix":"10.2169","volume":"54","author":[{"given":"Izumi","family":"Kurata","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroto","family":"Tsuboi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hidenori","family":"Takahashi","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Saori","family":"Abe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ebe","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shinya","family":"Hagiwara","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoto","family":"Umeda","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuya","family":"Kondo","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Ogishima","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Suzuki","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isao","family":"Matsumoto","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Hoshi","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tetsuro","family":"Oshika","sequence":"additional","affiliation":[{"name":"Department of Ophthalmology, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takayuki","family":"Sumida","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Faculty of Medicine, University of Tsukuba, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Nussenblatt RB. Uveitis in Beh&ccedil;et's disease. Int Rev Immunol 14: 67, 1997.","DOI":"10.3109\/08830189709116845"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Faezi ST, Paragomi P, Shahram F, et al. Clinical features of Behcet's disease in patients without oral aphthosis. Mod Rheumatol 24: 637-639, 2014.","DOI":"10.3109\/14397595.2013.844400"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Hatemi G, Silman A, Bang D, et al. EULAR recommendations for the management of Beh&ccedil;et disease. Ann Rheum Dis 67: 1656-1662, 2008.","DOI":"10.1136\/ard.2007.080432"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Maini RN, Breedveld FC, Kalden JR, et al. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41: 1552-1563, 1998.","DOI":"10.1002\/1529-0131(199809)41:9<1552::AID-ART5>3.0.CO;2-W"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Takeuchi T, Miyasaka N, Inoue K, Abe T, Koike T; RISING study. Impact of trough serum level on radiographic and clinical response to infliximab plus methotrexate in patients with rheumatoid arthritis: results from the RISING study. Mod Rheumatol 19: 478-487, 2009.","DOI":"10.3109\/s10165-009-0195-8"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Kaburaki T, Namba K, Sonoda KH, et al. Beh&ccedil;et's disease ocular attack score 24: evaluation of ocular disease activity before and after initiation of infliximab. Jpn J Ophthalmol 58: 120-130, 2014.","DOI":"10.1007\/s10384-013-0294-0"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Yee AM, Pochapin MB. Treatment of complicated sarcoidosis with infliximab anti-tumor necrosis factor-alpha therapy. Ann Intern Med 135: 27-31, 2001.","DOI":"10.7326\/0003-4819-135-1-200107030-00010"},{"key":"8","unstructured":"8. Singh R, Cuchacovich R, Huang W, Espinoza LR, et al. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol 29: 636-637, 2002."},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology 45: 357-359, 2006.","DOI":"10.1093\/rheumatology\/kei264"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Hueber AJ, Tunc A, Schett G, Manger B. Anti-tumour necrosis factor alpha therapy in patients with impaired renal function. Ann Rheum Dis 66: 981-982, 2007.","DOI":"10.1136\/ard.2006.069211"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Saougou I, Papagoras C, Markatseli TE, Voulgari PV, Drosos AA. A case report of a psoriatic arthritis patient on hemodialysis treated with tumor necrosis factor blocking agent and a literature review. Clin Rheumatol 29: 1455-1459, 2010.","DOI":"10.1007\/s10067-010-1485-4"},{"key":"12","unstructured":"12. Marocchi E, Spadaro A, Giannakakis K, Priori R, Valesini G. Infliximab in a patient with ankylosing spondylitis and secondary IgA nephropathy requiring haemodialysis. Clin Exp Rheumatol 28: 440, 2010."},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Kume K, Yamasaki M, Yoshikawa I, Harada M. Infliximab treatment in a patient with Crohn's disease on haemodialysis. Colorectal Dis 13: 34, 2011.","DOI":"10.1111\/j.1463-1318.2010.02217.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Ozyazgan Y, Yurdakul S, Yazici H, et al. Low dose cyclosporin A versus pulsed cyclophosphamide in Beh&ccedil;et's syndrome: a single masked trial. Br J Ophthalmol 76: 241-243, 1992.","DOI":"10.1136\/bjo.76.4.241"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Saleh Z. Update on the therapy of Beh&ccedil;et disease. Ther Adv Chronic Dis 5: 112-134, 2014.","DOI":"10.1177\/2040622314523062"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Vercauteren SB, Vercauteren SB, Bosmans JL, Elseviers MM, Verpooten GA, De Broe ME, et al. A meta-analysis and morphological review of cyclosporine-induced nephrotoxicity in auto-immune disease. Kidney Int 54: 536-545, 1998.","DOI":"10.1046\/j.1523-1755.1998.00017.x"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Keino H, Okada AA, Watanabe T, Taki W, et al. Decreased ocular inflammatory attacks and background retinal and disc vascular leakage in patients with Beh&ccedil;et's disease on infliximab therapy. Br J Ophthalmol 95: 1245-1250, 2011.","DOI":"10.1136\/bjo.2010.194464"},{"key":"18","unstructured":"18. Cantini F, Niccoli L, Nannini C, et al. Efficacy of infliximab in refractory Beh&ccedil;et's disease-associated and idiopathic posterior segment uveitis: a prospective, follow-up study of 50 patients. Biologics 6: 5-12, 2012."},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tabbara K, Al-Hemidan A. Infliximab effects compared to conventional therapy in the management of retinal vasculitis in Beh&ccedil;et disease. Am J Ophthalmol 146: 845-850, 2008.","DOI":"10.1016\/j.ajo.2008.09.010"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Yamada Y, Sugita S, Tanaka H, Kamoi K, Kawaguchi T, Mochizuki M. Comparison of infliximab versus ciclosporin during the initial 6-month treatment period in Beh&ccedil;et disease. Br J Ophthalmol 94: 284-288, 2010.","DOI":"10.1136\/bjo.2009.158840"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Markomichelakis N, Delicha E, Masselos S, Fragiadaki K, Kaklamanis P, Sfikakis PP. A single infliximab infusion versus corticosteroids for acute panuveitis attacks in Beh&ccedil;et's disease: a comparative 4-week study. Rheumatology 50: 593-597, 2011.","DOI":"10.1093\/rheumatology\/keq366"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Sumida K, Ubara Y, Suwabe T, et al. Adalimumab treatment in patients with rheumatoid arthritis with renal insufficiency. Arthritis Care Res 65: 471-475, 2013.","DOI":"10.1002\/acr.21800"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Martis P, Landucci L, Sundin U, et al. Trough s-infliximab and antibodies towards infliximab in a cohort of 79 IBD patients with maintenance infliximab treatment. J Crohns Colitis 8: 881-889, 2014.","DOI":"10.1016\/j.crohns.2014.01.009"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,23]],"date-time":"2017-06-23T13:42:58Z","timestamp":1498225378000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/12\/54_54.4274\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.4274","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}